Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease SAN DIEGO,...

Related Keywords

Japan ,Argentina ,United States ,Orlando ,Florida ,Buenos Aires ,Distrito Federal ,American ,Jula Inrig ,Exchange Commission ,American Nephrology Nurses Association ,European Commission ,Nasdaq ,National Symposium In Orlando ,World Congress ,Travere Therapeutics Inc ,National Symposium ,Subgroup Analyses ,Year Results ,Pivotal Phase ,Main Foyer ,First Line Treatment ,Incident Patients ,Iga Nephropathy ,Preliminary Findings ,Clinical Glomerulonephritis ,Label Extension ,Receptor Occupancy Modeling ,Clinical Actions ,Pediatric Patients ,Selected Proteinuric Glomerular ,Novel Non Immunosuppressive Therapy ,Humanistic Burdens ,Focal Segmental Glomerular Sclerosis ,External Controls ,Humanistic Burdens Between Patients ,Kidney Failure ,Treatment Effects ,Travere Therapeutics ,Important Safety ,Endothelin Receptor Antagonists ,Upper Limit ,Fetal Toxicity ,Kidney Injury ,Angiotensin System ,Acid Reducing Agents ,Steroidal Anti Inflammatory Agents ,Including Selective ,Increasing Serum Potassium ,Reproductive Potential ,Full Prescribing Information ,Private Securities Litigation Reform Act ,Markets ,